In females, strong discordance for VEGFR, PDGFR, and FLT3 blockade, coupled with suppression of mitotic-segregation pathways, argues for combining anti-angiogenic or RTK inhibitors with HDAC inhibitors and neuron-glioma coupling modulators (e.g., clinically tractable NMDAR antagonists). The gene discussed is FLT3; the disease is glioma.